Loading clinical trials...

RECRUITING

Prediction of Abdominal Aortic Aneurysm Shrinkage After Stent-placement With Artificial Intelligence

Prediction of Abdominal Aortic Aneurysm Shrinkage After Endovascular Repair With Artificial Intelligence

NCT06250998•Rijnstate Hospital

Summary

The goal of this observational study is to find out what factors contribute to a good treatment outcome in patients who have received a stent for their dilation of the main abdominal artery (abdominal aortic aneurysm or AAA). The primary goal of this study is to build a prediction model for abdominal aortic aneurysm shrinkage one year after the treatment.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age ≥ 18 years;
•Elective, initially technically successful (as described by the ESVS guidelines11), infrarenal EVAR for unruptured infrarenal AAA;
•Implanted endograft is a Gore Excluder, Medtronic Endurant, Cook Zenith, Cordis Incraft, Endologix AFX, Jotec E-Tegra, or Vascutek Anaconda endograft;
•Follow-up of the AAA of at least one year with imaging of the same modality as the preoperative imaging;
•Axial reconstructions of preoperative CT angiography available, preferably in the arterial phase and with 3 mm or smaller slice thickness.

Exclusion Criteria

•Patients with ruptured or symptomatic AAA;
•Patients that were treated with fenestrated or branched endografts, iliac branched devices, non-CE marked devices within trial setting, other endografts (EVAS cases) or chimney procedures;
•Acute procedures;
•Reintervention before one year follow-up;
•Revision cases after previous open or endovascular aneurysm repair of an AAA;

Locations (5)

Rijnstate Hospital

Arnhem, Non US/Canada, Netherlands

Amsterdam UMC

Amsterdam, Netherlands

Medisch Spectrum Twente

Enschede, Netherlands

Universitair Medisch Centrum Groningen

Groningen, Netherlands

Karolinksa Institutet

Stockholm, Sweden

Key Dates

Start Date

April 3, 2024

Primary Completion Date

May 1, 2024

Completion Date

June 1, 2024

Last Updated

April 11, 2024

Enrollment

1,000

ESTIMATED participants

Conditions

AAA - Abdominal Aortic Aneurysm

Contacts

Rianne E van Rijswijk, MSc

CONTACT

0031880057282 contact@radarconsortium.com

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

NCT06218875

AAA - Abdominal Aortic Aneurysm

View study

RECRUITINGNA

JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

NCT05064540

AAAAAA - Abdominal Aortic Aneurysm

View study

UNKNOWN

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 11, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Prediction of Abdominal Aortic Aneurysm Shrinkage After Stent-placement With Artificial Intelligence

Inclusion Criteria

Exclusion Criteria

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization

A Study of the Safety of Targeted AAA Screening

Cross-sectional Study of Prevalence Rate of Abdominal Aortic Aneurysm in OSAHS Patients From BTCH